pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis Wi
SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
CBP-201
Phase 2 · small molecule · Moderate-to-severe Atopic Dermatitis
CBP-201 for Moderate-to-severe Atopic Dermatitis is a Phase 2 program (small_molecule) at S.L with 2 ClinicalTrials.gov record(s).
Internal code CBP-201-CN002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- S.L
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Moderate-to-severe Atopic Dermatitis
- Status
- completed
- Trials
- 2